九典制藥(300705.SZ):洛索洛芬鈉凝膠貼膏近期中標浙江省集採 中標價17.37元/貼
格隆匯11月28日丨九典制藥(300705.SZ)近期在接待機構投資者調研時表示,洛索洛芬鈉凝膠貼膏去年中標了廣東聯盟地區集採,中標價格為18.19元/貼,截止目前聯盟地區基本都已執行,從廣東省、河南省的執行情況來看,較好的實現了以價換量。
洛索洛芬鈉凝膠貼膏近期中標了浙江省集採,中標價格為17.37元/貼。浙江省集採執行後將進一步擴大該產品的銷售範圍,提高其市場佔有率,提升公司的品牌影響力,對公司長遠發展產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.